AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

• Histologically or cytologically confirmed adenocarcinoma of the breast
• Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study
• All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
• Female > 18 years of age
• ECOG Performance status 0 and 1
• Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5
• Subject is willing and able to provide signed consent before any study-specific procedure

Other criteria also apply.